Despite the fact that COVID-19 vaccines are already available on the market, there have not been any effective FDA-approved drugs to treat this disease. There are several already known drugs that through drug repositioning have shown an inhibitory activity against SARS-CoV-2 RNA-dependent RNA polymerase. These drugs are included in the family of nucleoside analogues. In our efforts, we synthesized a group of new nucleoside analogues, which are modified at the sugar moiety that is replaced by a quinazoline entity. Different nucleobase derivatives are used in order to increase the inhibition. Five new nucleoside analogues were evaluated with in vitro assays for targeting polymerase of SARS-CoV-2.
All Keywords
【저자키워드】 COVID-19, nucleoside derivatives, quinazoline moiety, 【초록키워드】 SARS-CoV-2, COVID-19 vaccine, drug, In vitro assay, RNA-dependent RNA polymerase, disease, Nucleoside analogues, nucleoside analogue, FDA-approved drug, treat, inhibitory activity, derivative, sugar moiety, polymerase, effective, shown, evaluated, replaced, 【제목키워드】 SARS-CoV-2, nucleoside, targeting, analogue, New,
【저자키워드】 COVID-19, nucleoside derivatives, quinazoline moiety, 【초록키워드】 SARS-CoV-2, COVID-19 vaccine, drug, In vitro assay, RNA-dependent RNA polymerase, disease, Nucleoside analogues, nucleoside analogue, FDA-approved drug, treat, inhibitory activity, derivative, sugar moiety, polymerase, effective, shown, evaluated, replaced, 【제목키워드】 SARS-CoV-2, nucleoside, targeting, analogue, New,